Analyzing TriSalus Life Sciences (NASDAQ:TLSI) and Metastat (OTCMKTS:MTST)

TriSalus Life Sciences (NASDAQ:TLSI) and Metastat (OTCMKTS:MTST) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Profitability

This table compares TriSalus Life Sciences and Metastat’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-98.45%	N/A	-116.49%
Metastat	N/A	N/A	N/A

Earnings & Valuation

This table compares TriSalus Life Sciences and Metastat”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$29.43 million	7.73	-$30.05 million	($1.18)	-3.86
Metastat	N/A	N/A	N/A	N/A	N/A

Metastat has lower revenue, but higher earnings than TriSalus Life Sciences.

Volatility & Risk

TriSalus Life Sciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Metastat has a beta of 248.57, suggesting that its stock price is 24,757% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for TriSalus Life Sciences and Metastat, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1	0	4	0	2.60
Metastat	0	0	0	0	0.00

TriSalus Life Sciences currently has a consensus target price of $10.50, suggesting a potential upside of 130.26%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Metastat.

Institutional and Insider Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by insiders. Comparatively, 8.5% of Metastat shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

TriSalus Life Sciences beats Metastat on 6 of the 9 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Metastat

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.